301257.SZ
SMO ClinPlus Co., Ltd.
SZSE · M 科研服务 · CN
CNY 45.22
−6.80%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 860.1M | 842.5M | 803.7M | 760.0M | 586.2M |
| Cost of Revenue | 639.0M | 624.6M | 607.7M | 528.9M | 426.2M |
| Gross Profit | 221.0M | 217.9M | 196.0M | 231.1M | 160.0M |
| Operating Expenses | |||||
| R&D Expense | 38.5M | 38.8M | 35.8M | 34.8M | 32.2M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 45.6M | 45.1M | 43.8M | 41.8M | 44.2M |
| Selling & Marketing Expense | 9.3M | 9.1M | 8.6M | 8.5M | 5.7M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 96.5M | 96.5M | 91.0M | 83.4M | 79.2M |
| Cost and Expenses | 735.5M | 721.1M | 698.7M | 612.3M | 505.5M |
| Operating Income (EBIT) | 132.8M | 127.9M | 121.6M | 161.5M | 80.9M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 132.7M | 127.9M | 121.6M | 161.0M | 80.8M |
| Income Tax Expense | 18.5M | 18.2M | 15.2M | 26.3M | 8.4M |
| Bottom Line | |||||
| Net Income | 114.2M | 109.6M | 106.4M | 134.7M | 72.4M |
| Earnings from Cont. Ops | 114.2M | 109.6M | 106.4M | 134.7M | 72.4M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 114.2M | 109.6M | 106.4M | 134.7M | 72.4M |
| Per Share | |||||
| Basic EPS | CN¥1.45 | CN¥1.38 | CN¥1.35 | CN¥1.72 | CN¥1.35 |
| Diluted EPS | CN¥1.45 | CN¥1.38 | CN¥1.35 | CN¥1.71 | CN¥1.33 |
| Revenue Per Share | CN¥10.73 | CN¥10.60 | CN¥10.19 | CN¥9.70 | CN¥10.93 |
| Shares | |||||
| Basic Shares Outstanding | 80.2M | 79.4M | 78.8M | 78.3M | 53.6M |
| Diluted Shares Outstanding | 80.2M | 79.4M | 78.8M | 78.3M | 53.6M |
| Profitability Metrics | |||||
| EBITDA | — | 135.2M | 127.9M | 166.5M | 85.1M |
| D&A | — | 7.3M | 6.3M | 5.1M | 4.3M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026